Antibiotice Sa · BVB:ATB
Antibiotice Sa — Investor Presentation (November 2019)
31 slides from Antibiotice Sa's investor presentation, November 2019
Slide 1: Antibiotice - Company Presentation
a c e@ 2 © wo Antibiotice Stiinta si suflet
Slide 2: A brief history of Antibiotice
A brief history of Antibiotice 1955 1955-1990 1990-1999 2000-2010 a+ The first company Our company enlarged its Manufacturing structure manufacturing Penicillin was continuously Our company massively invested manufacturing structure with to modernize the technologies and in Romania and redefined
Slide 3: A brief history of Antibiotice
A brief history of Antibiotice 2010 2015 Present Our company opened its own Center for Antibiotice has become a world leader in the Drug Evaluation; production of Nystatin; It has become the first European WHO pre- Our product portofolio comprises more than qualified company for anti-tuberculosis 15
Slide 4: Mission, Vision, Values
Mission, Vision, Values07 JUNE 2017 MISSION We make our valuable medicines more accessible to patients, physicians and pharmacists. We always put our strength to the service of those who need our support. VISION The Hippocratic spirit that guides the practice of medicine and pharmacy also guides our
Slide 5: Shareholding and evolution of shares
Shareholding and evolution of shares S.I.F. Oltenia 18.8999 % Bucharest Stock Exchange ATB Other Ministry of Health shareholders Number of shares 671,338,040 28.0829% 53.02 % Nominal value of shares 0.1000 LEI Market capitalization – 30.09.2019 342,382 thousand LEI Evolution of number of traded shar
Slide 6: 22 years in the capital market
22 years in the capital market April 1997 2005 2007 Antibiotice, listed in the Premium ATB shares have been included in the ATB shares have been included in the Dow category of the Bucharest Stock ROTX index of the Vienna Stock Jones Wilshire Global Total Market index of Exchange Exchange the New Yo
Slide 7: Strategic development pillars
Strategic development pillars We Investments We adapt our Our business expands strategically - human Integrated internationally and adjust our the guarantee resources at the quality strengthens product for a bright management strategic internally portfolio future directions BVB symbol: ATB www.antib
Slide 8: Our business expands internationally
Our business expands internationally EXPORT 42 % din total vânzări Our own representative 10% Russia offices in the Republic 19% Europe & CIS of Moldova, Ukraine and Serbia 23% 40% Vietnam North Asia America 50 internationally registered 2% products Africa World leading manufacturer of 36 million US
Slide 9: Strategies for internationalizing our business
Strategies for internationalizing our business To strengthen our leading position in the Nystatin market To expand our presence in North America and in the territories with Antibiotice representative offices A DOUBLED TURNOVER UNTIL 2025 To access new markets with a high consumption potential for ou
Slide 10: Antibiotice today
Antibiotice today Market The most important Romanian manufacturer of share GENERICS 1 generic medicines 10% World leader in the production of Nystatin - Active WORLDWIDE 1 active substance 65% substance 1 Leader in the production of injectable beta-lactam 84% Market INJECTABLES antibiotics in Romani
Slide 11: Antibiotice today
Antibiotice today 70 An internationally present company 35% COUNTRIES It invests 5% of turnover in 5 5% R&D research – development projects A portfolio comprising more than 150 products from the following therapeutic areas – antiinfectives, 150 THERAPUTIC 11 cardiovasculars, dermatologicals, digesti
Slide 12: National pharmaceutical market
National pharmaceutical market NAMMDR – issues the Marketing Autorizations - Law no. 95/2006 updated Legislation RX pricing regulation – Order no. 368/2017 updated - RX – Prescription medicines We provide - OTC – Non-prescription medicines - Food supplements and dermatocosmetics Alliance Healthcare
Slide 13: Romanian pharmaceutical market
Romanian pharmaceutical market Romanian market 17.5 billion LEI 100% Relevant market 2.07 billion LEI 12% Antibiotice market 340.04 million LEI 2% RETAIL HOSPITAL 88% 12% Romanian market 77% 23% Antibiotice market *Data source: Cegedim Romania July 2018 - June 2019 BVB symbol: ATB www.antibiotice.ro
Slide 14: Antibiotice in the national market
Antibiotice in the national market Partner of the Ministry of Health on the TB VALUE QUANTITY program, with a 90.5% market share of total consumption. 22% 35% Leader in the ointment segment in terms of units 78% 65% sold (23.9% market share in indivisible units). RX OTC Leader in the suppository seg
Slide 15: Consolidated portfolio in prospective therapeutic areas
Consolidated portfolio in prospective therapeutic areas Hospital & Partners Semisolid and solid topicals (ointments, creams, gels, pessaries and suppositories Life quality Women's health Cardiovasculars Nutriensa® BVB symbol: ATB www.antibiotice.ro
Slide 16: Hospital portfolio
Hospital portfolio Hospital & Partners Well-known manufacturer of injectable and oral anti-infectives It covers up all the subclasses of antibiotics Investments for expanding the hospital portfolio in the international market penicillins, cephalosporins, carbapenems, polymyxins. In Vietnam Our compa
Slide 17: Semisolid and solid topicals; Life quality
Semisolid and solid topicals (ointments, creams, gels, pessaries and suppositories A new manufacturing plant for topicals – a doubled production capacity; The range of 38 molecules (ointments, creams, gels and suppositories), recommendations in the medical guidelines for psoriasis, osteoarthritis /
Slide 18: Research & Development
Research & Development 10 million EUR investment 13-15 new projects/year 100 SPECIALISTS CENTER FOR CLINICAL STUDIES . Fields of activity: Our accumulated knowledge and Pharmaceutical development & experience allow us to develop future analytical research projects oriented towards the health of pati
Slide 19: Multidisciplinary R&D team
Multidisciplinary R&D team The key component of our development approach 32 21 Pharmacists 5 Chemists Biologists 1 10 Our specialists are licensed in fields Biochemists such as : Physicians 29 1 Chemical 3 Bioengineers engineers More than 35% of our R&D Physicists specialists have a PhD. BVB symbol:
Slide 20: Production adjusted to the market's demands
Production adjusted to the market’s demands 8 GMP and FDA authorized manufacturing flows - a portfolio of generics from 11 therapeutic areas Anti-infectives for systemic use Dermatologicals Cardiovasculars Digestive tract and metabolism Central nervous system Musculoskeletal system Genito-urinary sy
Slide 21: Investments – the guarantee for a bright future
Investments – the guarantee for a bright future 15% of total income assigned for investments The medium- and long-term development is based on: Investments in IT infrastructure and for Investments in modernizing the product quality interior and exterior Investments in new control, of the company fac
Slide 22: We keep investing in
We keep investing in A new manufacturing plant for ointments & suppositories 20 million EUR Manufacturing plant for sterile injectable solutions Upgrading and expanding the Biosynthesis Plant in which the active substance Nystatin is manufactured and in diversifying the product range 60 million EUR
Slide 23: Strategic objectives of the human resource policy
Strategic objectives of the human resource policy To support the professional performance and career development Partner of the university system To create a balanced staff structure To improve the organizational climate Specialists with The most important experience in employer with a research, qua
Slide 24: Diversity and high professional qualification
Diversity and high professional qualification 29.10 % 15.80 % 7.80 % 11.60 % 23 % 3.2 % 10 % Chemists, Physicists, Doctors and Engineers of different Biologists Economists IT specialists Other areas Chemical Engineers Pharmacists specializations We owe our success to our highly qualified specialists
Slide 25: Attractive brand for our future employees
Attractive brand for our future employees Initiatives aimed at ensuring the training of the skills needed to reach the objectives and increase the degree of involvement Projects in progress Projects in perspective Academia+ Students with various specializations (biologists, chemists, chemical engine
Slide 26: Integrated quality management system
Integrated quality management system US - FDA for sterile injectable powders and the active substance Nystatin Integrated quality management system (quality, environment, occupational health and security) CoS (Certificate of Suitability) for micronized Nystatin issued by EDQM Our active substance Ny
Slide 27: We design a high-performing future
We design a high-performing future Turnover Export Profit million LEI million LEI Million LEI 160 140 40 450 403 140 35 35 400 124 35 365 32 331 120 350 30 300 100 92,7 25 243,6 250 80 20 18 200 57,1 60 15 150 100 40 10 50 20 5 0 0 2010 2015 2018 2019(E) 0 2010 2015 2018 2019(E) 2010 2015 2018 2019(
Slide 28: People, community and environment - our main responsibilities
People, community and environment - our main responsibilities We produce medicines with science and we put our soul in what we do. We take the responsibility to contribute as a "good citizen" to the life of our community, directly involving ourselves in developing a better society and a cleaner envi
Slide 29: Thank you!
Thank you! Contact: Investor Relations Tel: 0232 – 209 583 Email: relatiicuinvestitorii@antibiotice.ro BVB symbol: ATB www.antibiotice.ro
Slide 30: Financial indicators
Financial indicators No. Indicators UM 2016 2017 2018 06/30/2019 1 Sales income Mil Lei 332 336.9 365 172 1,1 Internal Mil Lei 227.4 219.4 241 100 1,2 Export Mil Lei 105 117.5 124 72 1,3 Export weight in turnover % 32% 35% 34% 42% 2 Gross profit Mil Lei 35 35 35 25 3 Equity Mil Lei 409 417 473 488 4
Slide 31: Disclaimer
Disclaimer This presentation does not constitute and should not be construed as representing or being part of any current offer to sell or issue shares, or as a purchase or subscription request for any shares issued by Antibiotice S.A. No part of this presentation may be invoked in connection with a